Introduce Talquetamab in Subcu, Perc, New Tech 9

This code describes the administration of talquetamab, a novel antineoplastic agent, directly into the subcutaneous tissue. This procedure is performed percutaneously, meaning through the skin, to deliver the medication for cancer treatment. Talquetamab is a bispecific antibody used in the treatment of multiple myeloma.

This code is used when a patient with multiple myeloma receives talquetamab via subcutaneous injection. This typically occurs in an outpatient or inpatient setting as part of a planned treatment regimen. It specifically applies to the initial or subsequent administrations of this particular drug.

• Verify that talquetamab was the specific antineoplastic agent introduced.
• Confirm the route of administration was subcutaneous and percutaneous.
• Ensure documentation supports the use of this new technology agent for appropriate billing.